Format

Send to

Choose Destination
Cancer Res. 2017 Jan 15;77(2):312-319. doi: 10.1158/0008-5472.CAN-16-1873. Epub 2016 Nov 21.

PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors.

Charlebois R1,2, Allard B1,2,3, Allard D1,2,3, Buisseret L1,2,3,4,5, Turcotte M1,2,3, Pommey S1,2,3, Chrobak P1,2,3, Stagg J6,2,3.

Author information

1
Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada.
2
Institut du Cancer de Montréal, Montréal, Québec, Canada.
3
Faculté de Pharmacie, Université de Montréal, Québec, Canada.
4
Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
5
Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
6
Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada. john.stagg@umontreal.ca.

Abstract

Innate and adaptive immune cells play an important role in the therapeutic activity of anti-ErbB2 mAbs, such as trastuzumab. In the clinic, breast tumors poorly infiltrated with immune cells are more resistant to trastuzumab, and patients have a worse prognosis. Because type I and II IFNs are critical to the immune-mediated activity of anti-ErbB2 mAb, we investigated the effect of combining polyI:C and CpG with trastuzumab-like therapy in immunocompetent mouse models of ErbB2+ breast cancer. We demonstrated that in situ delivery of polyI:C and CpG combined to systemic anti-ErbB2 mAb triggered a potent inflammatory response in breast tumors able to induce long-lasting CD8+ T cell-dependent antitumor immunity. Remarkably, polyI:C and CpG was superior to combined PD-1/CTLA-4 blockade in sensitizing tumors to anti-ErbB2 mAb therapy. Local injection of CpG and polyI:C in a primary tumor significantly enhanced the activity of systemic anti-ErbB2 mAb against a distant untreated tumor. Type I and II IFNs, as well as natural killer cells and CD8+ T cells, were indispensible to the synergistic activity of the combination treatment. Because synthetic RNA analogues and CpG oligodeoxynucleotides have been safely used in clinical trials, our study supports combination treatments with anti-ErbB2 mAbs. Cancer Res; 77(2); 312-9.

PMID:
27872096
DOI:
10.1158/0008-5472.CAN-16-1873
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center